Scholarlink

Research question <p>While growth hormone (GH) is hypothesized to potentially enhance embryo quality, results of current basic and clinical researches remain inconclusive. This study assesses the effect of GH supplementation on embryo quality and explores the relationship between baseline insulin-like growth factor-1 (IGF-1) levels and the efficacy of GH supplementation among Chinese patients undergoing in vitro fertilization (IVF).</p> Design <p>A randomized controlled Open-label trial was performed with 128 women experiencing poor embryonic development in IVF. Participants were allocated to the GH group (GH + Gonadotropin-Releasing Hormone [GnRH] antagonist protocol) and the Control group (GnRH antagonist protocol). The primary outcome was the number of high-quality embryos on Day 3.</p> Results <p>Patients in the GH group required significantly lower total doses of gonadotropin (2213 ± 667 IU vs. 2573 ± 630 IU, <i>p</i> = 0.0058) and shorter duration of controlled ovarian stimulation (10.1 ± 1.60 days vs. 10.6 ± 1.30 days, <i>p</i> = 0.0488). While there was no statistically significant overall increase in the number of high-quality embryos, subgroup analysis indicated that patients with lower baseline IGF-1 levels, especially those below the lowest quartile, might show a higher rate of high-quality embryos with GH supplementation (<i>p</i> = 0.0488). Additionally, the fresh embryo transfer clinical pregnancy rate was numerically higher in the GH supplementation group (46.2%) compared to the control group (38.5%), although not statistically significant.</p> Conclusions <p>This study suggests that GH co-treatment may enhance ovarian responsiveness in IVF patients with poor embryo quality, thereby reducing the dosage and duration of Gonadotropin (Gn) administration. Among individuals with lower IGF-1 levels, adding GH may improve the rate of high-quality embryos, highlighting the potential benefits of personalized treatment strategies in IVF.</p> Clinical trial registration <p>ClinicalTrials.gov ID: NCT03966339 (Registration time: 2019-05-24).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Exploring the potential benefits of growth hormone co-treatment on embryo quality in IVF: a randomized controlled open-label trial

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年3月15日

查看全文
  • Yi Tang,
  • Xiaofeng Li,
  • Change Hu,
  • Ruyi Guan,
  • Zhimin Wang,
  • Shunji Zhang,
  • Guoping Tao,
  • Jingfei Qu,
  • Fei Gong

摘要

Research question

While growth hormone (GH) is hypothesized to potentially enhance embryo quality, results of current basic and clinical researches remain inconclusive. This study assesses the effect of GH supplementation on embryo quality and explores the relationship between baseline insulin-like growth factor-1 (IGF-1) levels and the efficacy of GH supplementation among Chinese patients undergoing in vitro fertilization (IVF).

Design

A randomized controlled Open-label trial was performed with 128 women experiencing poor embryonic development in IVF. Participants were allocated to the GH group (GH + Gonadotropin-Releasing Hormone [GnRH] antagonist protocol) and the Control group (GnRH antagonist protocol). The primary outcome was the number of high-quality embryos on Day 3.

Results

Patients in the GH group required significantly lower total doses of gonadotropin (2213 ± 667 IU vs. 2573 ± 630 IU, p = 0.0058) and shorter duration of controlled ovarian stimulation (10.1 ± 1.60 days vs. 10.6 ± 1.30 days, p = 0.0488). While there was no statistically significant overall increase in the number of high-quality embryos, subgroup analysis indicated that patients with lower baseline IGF-1 levels, especially those below the lowest quartile, might show a higher rate of high-quality embryos with GH supplementation (p = 0.0488). Additionally, the fresh embryo transfer clinical pregnancy rate was numerically higher in the GH supplementation group (46.2%) compared to the control group (38.5%), although not statistically significant.

Conclusions

This study suggests that GH co-treatment may enhance ovarian responsiveness in IVF patients with poor embryo quality, thereby reducing the dosage and duration of Gonadotropin (Gn) administration. Among individuals with lower IGF-1 levels, adding GH may improve the rate of high-quality embryos, highlighting the potential benefits of personalized treatment strategies in IVF.

Clinical trial registration

ClinicalTrials.gov ID: NCT03966339 (Registration time: 2019-05-24).